Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Daunorubicin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for daunorubicin hydrochloride and what is the scope of daunorubicin hydrochloride freedom to operate?

Daunorubicin hydrochloride
is the generic ingredient in two branded drugs marketed by Fresenius Kabi Usa, West-ward Pharms Int, Teva Parenteral, Teva Pharms Usa, Sanofi Aventis Us, and Wyeth Ayerst, and is included in eight NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for daunorubicin hydrochloride. One supplier is listed for this compound.

Summary for Generic Name: daunorubicin hydrochloride

Tradenames:2
Patents:1
Applicants:6
NDAs:8
Drug Master File Entries: see list11
Suppliers / Packagers: see list1
Bulk Api Vendors: see list61
Clinical Trials: see list1,061
Patent Applications: see list7,799
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:daunorubicin hydrochloride at DailyMed

Pharmacology for Ingredient: daunorubicin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West-ward Pharms Int
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride
INJECTABLE;INJECTION050731-001Jan 30, 1998APRXYesYes► Subscribe► Subscribe
Teva Parenteral
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride
INJECTABLE;INJECTION064212-001Jun 23, 1998DISCNNoNo► Subscribe► Subscribe
Fresenius Kabi Usa
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride
INJECTABLE;INJECTION065000-001May 25, 1999APRXNoNo► Subscribe► Subscribe
Teva Parenteral
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride
INJECTABLE;INJECTION064212-002May 3, 1999DISCNNoNo► Subscribe► Subscribe
Fresenius Kabi Usa
DAUNORUBICIN HYDROCHLORIDE
daunorubicin hydrochloride
INJECTABLE;INJECTION065034-001Nov 20, 2001RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot